A Study to Evaluate Topically Applied SXR1096 Cream in Patients With Netherton Syndrome
Status:
Recruiting
Trial end date:
2022-12-20
Target enrollment:
Participant gender:
Summary
In this phase I/II trial a topical skin cream with the active substance SXR1096 will be
tested in patients with Netherton syndroms, a rare inflammatory skin disease. SXR1096 is a
specific and potent protease inhibitor that can inhibit the proteases kallikrein 5, 7 and 14
- all recognised as up-regulated and causing the disease state in Netherton syndrome
patients. Patients will be treated for one month with active cream and placebo cream at
different areas of the skin.